Detail akcie Kamada Ltd online

Business Summary: Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Kamada Ltd revenues increased 12% to $180.5M. Net income increased 40% to $20.2M. Revenues reflect Proprietary Products segment increase of 10% to $156.2M, Distribution segment increase of 24% to $24.3M, Latin America segment increase of 30% to $24.2M, Israel segment increase of 18% to $29.6M. Net income benefited from Revaluation of long-term liabilities decrease of 67% to $2.7M (expense).